Takeda fleshes out case for oral EGFR drug with follow-up pivotal data in non-small cell lung cancer

Takeda is looking to carve out a major niche in non-small cell lung cancer with an oral TKI inhibitor targeting a rare but desperate patient population. Now, with the FDA already checking its math, Takeda is unveiling updated data adding even more heft to that drug’s case.